CDK5R2 Antibody

What are the key considerations when selecting a CDK5R2/p39 antibody for neuronal research?

When selecting a CDK5R2 antibody for neuronal research, consider:

• Epitope specificity: Select antibodies targeting specific regions (e.g., N-terminal, internal region, or full-length protein). For comprehensive studies, antibodies recognizing the full-length human CDK5R2 (AA 1-367) provide complete coverage .

• Host species compatibility: Ensure the host species (typically mouse or rabbit) is compatible with your experimental design, particularly for co-staining experiments. Most commercial CDK5R2 antibodies are available as rabbit or mouse polyclonal antibodies .

• Validated applications: Verify the antibody has been validated for your specific application (WB, IHC, ICC, ELISA). For example, some CDK5R2 antibodies are specifically validated for Western Blotting at dilutions of 1:500-1:1000, while others may be optimized for immunohistochemistry at 1:50-1:500 .

• Species reactivity: Confirm reactivity with your experimental model (human, mouse, rat). Many CDK5R2 antibodies demonstrate cross-reactivity with human, mouse, and rat samples, but specificity should be verified .

• Clonality consideration: Polyclonal antibodies may provide stronger signals but potentially more background, while monoclonal antibodies offer higher specificity but potentially lower sensitivity.

How can I validate a CDK5R2 antibody before using it in critical experiments?

Comprehensive validation should include:

• Western blot analysis: Run samples from tissues known to express CDK5R2 (particularly brain tissue) alongside negative controls. CDK5R2 should appear at approximately 39 kDa . If possible, include lysates from CDK5R2 knockout models or siRNA-treated cells.

• Cross-reactivity testing: Test for cross-reactivity with closely related proteins, particularly CDK5R1 (p35), which shares functional similarity with CDK5R2.

• Immunoprecipitation validation: Perform IP followed by Western blot to confirm the antibody's specificity and ability to recognize native protein.

• Immunohistochemistry controls: Include positive controls (brain tissue sections) and negative controls (non-neuronal tissues with minimal CDK5R2 expression or primary antibody omission).

• Batch-to-batch consistency check: When obtaining a new lot of the same antibody, perform side-by-side comparisons with the previous lot to ensure consistent reactivity patterns.

• Peptide competition assay: Pre-incubate the antibody with excess purified CDK5R2 peptide to confirm signal specificity.

What is the optimal protocol for immunoprecipitating CDK5R2 for subsequent kinase activity assays?

For optimal CDK5R2 immunoprecipitation prior to kinase activity assessment:

• Sample preparation:

  • Prepare tissue/cell lysates in a non-denaturing buffer containing protease and phosphatase inhibitors

  • Use approximately 0.5 μg of total protein for optimal results

• Immunoprecipitation:

  • Incubate lysates with 2 μg of anti-CDK5R2 antibody for 1 hour at 4°C

  • Add magnetically labeled protein G or A microbeads and incubate for 30 minutes on ice

  • Perform washing steps according to the magnetic bead protocol to remove non-specific proteins

• Kinase activity assessment:

  • For radioactive assay: Incubate the immunoprecipitated complex with kinase buffer, histone H1 (5 μg), and [γ-32P]ATP (5 μCi) at 30°C for 20 minutes

  • Analyze phosphorylated substrate by SDS-PAGE followed by autoradiography

  • For quantification, excise protein bands corresponding to histone H1 and measure radioactivity by liquid scintillation counting

• Alternative non-radioactive approach:

  • Use non-radioactive ATP and detect phosphorylated substrate with phospho-specific antibodies via Western blot

  • Alternatively, employ commercially available CDK5R2 colorimetric cell-based ELISA kits that detect both total CDK5R2 and its activated form

What are the recommended dilutions and conditions for Western blot detection of CDK5R2?

For optimal Western blot detection of CDK5R2:

• Sample preparation:

  • For neuronal samples, use RIPA buffer with protease inhibitors

  • Include phosphatase inhibitors if phosphorylation status is important

  • Load 20-40 μg of total protein per lane

• Gel electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation

  • Transfer to PVDF membrane (recommended over nitrocellulose for phospho-proteins)

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk or BSA in TBST

  • Primary antibody dilution: 1:500-1:1000 is typically recommended for CDK5R2 antibodies

  • Incubate overnight at 4°C for optimal results

  • Secondary antibody dilution: 1:2000-1:5000 depending on detection system

• Detection specifics:

  • Expected molecular weight: 39 kDa

  • Positive controls: Mouse or rat brain tissue lysates, Neuro-2a cells

  • Loading control: GAPDH is commonly used as per validation protocols

• Troubleshooting considerations:

  • If signal is weak, consider longer exposure times or enhanced chemiluminescence substrates

  • If background is high, increase washing steps or optimize blocking conditions

  • For mouse antibodies on mouse tissue, use mouse-on-mouse blocking reagents to reduce background

How should I design experiments to distinguish between CDK5R1 (p35) and CDK5R2 (p39) activation of CDK5?

Differentiating between CDK5R1 and CDK5R2 activation of CDK5 requires careful experimental design:

• Specific antibody selection:

  • Use antibodies specifically targeting unique epitopes of CDK5R1 (p35) versus CDK5R2 (p39)

  • Validate antibody specificity through Western blot against recombinant proteins

• Co-immunoprecipitation studies:

  • Perform IP with CDK5-specific antibodies followed by Western blot with either CDK5R1 or CDK5R2 antibodies

  • Alternatively, immunoprecipitate with CDK5R1 or CDK5R2 antibodies and probe for CDK5

• RNA interference approach:

  • Use specific siRNAs or shRNAs to selectively knockdown CDK5R1 or CDK5R2

  • Assess the impact on CDK5 activity through kinase assays

• Kinase activity comparison:

  • Following immunoprecipitation with specific antibodies, compare kinase activity using histone H1 as substrate

  • Quantify phosphorylation levels to determine relative contributions of each activator

• Tissue-specific expression analysis:

  • Exploit differential expression patterns (CDK5R1 is more widely expressed, while CDK5R2 shows more restricted neuronal expression)

  • Use tissue-specific lysates to determine predominant activator

• Sequential immunodepletion:

  • Deplete lysates of CDK5R1 through immunoprecipitation, then assess remaining CDK5 activity (attributable to CDK5R2)

  • Repeat with CDK5R2 depletion to determine CDK5R1 contribution

How can I address inconsistent CDK5R2 antibody performance across different neuronal samples?

When facing inconsistent CDK5R2 antibody performance:

• Sample preparation variables:

  • Ensure consistent extraction methods across all samples

  • Verify protein integrity through Ponceau S staining or housekeeping protein detection

  • Consider the impact of post-translational modifications on epitope accessibility

• Antibody-specific considerations:

  • Test multiple antibodies targeting different epitopes of CDK5R2

  • For Western blot inconsistencies, try both reducing and non-reducing conditions

  • For IHC/ICC, optimize antigen retrieval methods (both TE buffer pH 9.0 and citrate buffer pH 6.0 have been validated)

• Expression level variations:

  • CDK5R2 expression varies by brain region and developmental stage

  • Quantitative PCR can verify transcript levels to correlate with protein detection

  • Consider using semiquantitative RT-PCR as described in the literature

• Signal enhancement strategies:

  • For low abundance samples, use signal amplification systems

  • Consider tyramide signal amplification for immunohistochemistry

  • For Western blots, longer exposure times or more sensitive substrates may help

• Technical validation:

  • Include recombinant CDK5R2 protein as a positive control

  • Use brain tissue samples as biological positive controls

  • Ensure antibody storage conditions are optimal (aliquot and store at -20°C with glycerol)

What are the most common pitfalls when interpreting CDK5R2 immunostaining patterns in brain tissue?

Common pitfalls and their solutions include:

• Background vs. specific staining:

  • CDK5R2 has neuronal specificity but may show variable expression levels

  • Compare with in situ hybridization data to confirm expression patterns

  • Use appropriate negative controls (primary antibody omission, non-neuronal tissues)

• Cross-reactivity concerns:

  • CDK5R2 and CDK5R1 share structural similarities

  • Verify staining patterns with antibodies targeting different epitopes

  • Consider dual immunofluorescence with CDK5R1 and CDK5R2 antibodies to distinguish patterns

• Subcellular localization interpretation:

  • CDK5R2 may show both cytoplasmic and membrane localization

  • Use confocal microscopy for accurate subcellular localization

  • Co-stain with subcellular markers to verify compartmentalization

• Developmental and activity-dependent changes:

  • CDK5R2 expression may change during development or neuronal activity

  • Standardize tissue collection timing and conditions

  • Document animal age and treatment conditions precisely

• Fixation and processing artifacts:

  • Overfixation can mask epitopes

  • Different fixatives may yield different staining patterns

  • Compare perfusion-fixed with immersion-fixed tissues to identify artifacts

How can I design experiments to measure the differential activation of CDK5 by CDK5R2 versus CDK5R1 following neuronal injury?

To investigate differential activation following neuronal injury:

• Time-course analysis:

  • Collect samples at multiple time points post-injury (30 min, 1.5h, 3h, 24h)

  • Analyze both mRNA (RT-PCR) and protein levels (Western blot) of CDK5R1 and CDK5R2

  • Research has shown transient upregulation of related factors 30 minutes after stress, returning to baseline within 1.5 hours

• Calpain activity measurement:

  • CDK5R1 (p35) can be cleaved by calpain to p25, altering CDK5 activity

  • Measure calpain activity in parallel with CDK5 activity

  • Compare CDK5R1 cleavage patterns with CDK5R2 stability

• Subcellular fractionation:

  • Separate nuclear, cytoplasmic, and membrane fractions

  • Compare distribution and activation of CDK5 by CDK5R1 vs. CDK5R2 in different compartments

• Inhibitor studies:

  • Use butyrolactone I as a CDK5 inhibitor to establish baseline effects

  • Compare neuronal survival and functional outcomes when specifically blocking either CDK5R1 or CDK5R2

• Immunoprecipitation kinase assays:

  • Immunoprecipitate CDK5 complexes using antibodies specific to CDK5R1 or CDK5R2

  • Compare kinase activities using histone H1 phosphorylation

  • Analyze substrate specificity differences between CDK5R1/CDK5 and CDK5R2/CDK5 complexes

• In vivo models:

  • Use conditional knockout models specific for either CDK5R1 or CDK5R2

  • Compare injury responses and recovery patterns

  • Assess downstream phosphorylation of targets like tau, MAP1B, or other cytoskeletal proteins

What methodological approaches can distinguish the roles of CDK5R2/CDK5 complexes in normal neurodevelopment versus neurodegenerative conditions?

To distinguish normal versus pathological roles:

• Temporal expression profiling:

  • Map CDK5R2 expression throughout neurodevelopment using Western blot and IHC

  • Compare with expression in age-matched neurodegenerative models

  • Correlate with CDK5 activity measurements using kinase assays

• Substrate phosphorylation patterns:

  • Use phospho-specific antibodies against known CDK5 substrates (MAPT/tau, MAP1B, CRMP2)

  • Compare phosphorylation patterns between developmental and pathological conditions

  • Perform proteomic analysis to identify differential substrate targeting

• Interactome analysis:

  • Use proximity labeling techniques (BioID, APEX) with CDK5R2 as bait

  • Compare interacting partners in developing versus degenerating neurons

  • Validate key interactions through co-immunoprecipitation

• Live imaging approaches:

  • Express fluorescently tagged CDK5R2 to monitor localization and dynamics

  • Compare trafficking and stability in healthy versus stressed neurons

  • Correlate with cytoskeletal remodeling and neurite growth/retraction

• Genetic manipulation strategies:

  • Use inducible expression systems to control CDK5R2 levels at specific developmental timepoints

  • Compare with overexpression in mature neurons to mimic pathological conditions

  • Assess consequences on neuronal morphology and connectivity

• Therapeutic intervention assessment:

  • Test CDK5 inhibitors at different developmental stages

  • Compare efficacy and side effects in developmental versus degenerative contexts

  • Develop CDK5R2-specific modulating compounds to selectively target pathological activation

How should I design experiments to investigate the potential differential phosphorylation of substrates by CDK5 when activated by CDK5R2 versus CDK5R1?

For investigating differential substrate phosphorylation:

• In vitro kinase assays with purified components:

  • Express and purify recombinant CDK5, CDK5R1, and CDK5R2

  • Perform kinase assays with potential substrates under identical conditions

  • Compare phosphorylation efficiency and site specificity

• Phosphoproteomic approach:

  • Establish cellular models with selective expression of either CDK5R1 or CDK5R2

  • Perform phosphoproteomic analysis to identify differentially phosphorylated substrates

  • Validate key targets with phospho-specific antibodies

• Peptide array analysis:

  • Use peptide arrays containing potential CDK5 substrates

  • Compare phosphorylation patterns when CDK5 is activated by CDK5R1 versus CDK5R2

  • Identify consensus motifs specific to each activator complex

• Structural biology insights:

  • If available, utilize structural data on CDK5/CDK5R1 and CDK5/CDK5R2 complexes

  • Model substrate binding differences

  • Design validation experiments based on structural predictions

• Cellular validation:

  • Express phosphorylation-deficient mutants of key substrates

  • Assess functional consequences in the presence of CDK5R1 versus CDK5R2

  • Use CRISPR/Cas9 to generate CDK5R1 or CDK5R2 knockout lines for clean comparison

• Temporal dynamics:

  • Compare substrate phosphorylation kinetics between the two activators

  • Assess dephosphorylation rates and stability of modifications

  • Investigate potential feedback mechanisms that might differ between activator complexes

What controls should be included when developing a colorimetric cell-based ELISA to simultaneously detect CDK5R2 and GAPDH in neuronal samples?

For robust cell-based ELISA development:

• Antibody validation controls:

  • Validate both anti-CDK5R2 and anti-GAPDH antibodies by Western blot

  • Prepare 1:100 dilutions of both primary antibodies using the appropriate Primary Antibody Diluent

  • Test antibodies separately before multiplexing

• Sample preparation controls:

  • Include both positive controls (cells known to express CDK5R2) and negative controls (non-neuronal cells)

  • Prepare standardized cell numbers per well (typically >5000 cells) to establish linear detection range

  • Test multiple fixation methods to determine optimal epitope preservation

• Assay validation controls:

  • Include wells with no primary antibody to establish background signal

  • Prepare standard curves using recombinant CDK5R2 protein

  • Include wells with GAPDH detection only to verify normalization

• Data analysis controls:

  • Establish signal-to-noise ratios for various cell densities

  • Determine the linear range of detection for both proteins

  • Include dilution series to verify proportional signal reduction

• Cell manipulation controls:

  • Include wells with CDK5R2 knockdown cells

  • Compare treated vs. untreated samples to verify response detection

  • Consider positive control treatments known to alter CDK5R2 levels

How can I design experiments to investigate the potential role of CDK5R2/CDK5 in regulating the circadian clock in neurons?

To investigate CDK5R2's role in circadian regulation:

• Temporal expression profiling:

  • Collect neuronal samples across circadian time points (every 4 hours for 24-48 hours)

  • Measure CDK5R2 mRNA and protein levels using qPCR and Western blot

  • Correlate with CDK5 activity using kinase assays

• Clock protein interaction studies:

  • Investigate interactions between CDK5R2/CDK5 and core clock proteins (CLOCK, BMAL1)

  • Use co-immunoprecipitation to detect physical interactions

  • The CDK5/p35 complex has been shown to phosphorylate CLOCK at Thr-451 and Thr-461; investigate if CDK5R2/CDK5 performs similar functions

• Phosphorylation site analysis:

  • Use phospho-specific antibodies to detect CLOCK phosphorylation at Thr-451 and Thr-461

  • Compare phosphorylation patterns when CDK5 is activated by CDK5R1 versus CDK5R2

  • Perform site-directed mutagenesis of these phosphorylation sites to assess functional consequences

• Subcellular localization studies:

  • Track circadian changes in CDK5R2 and CLOCK protein subcellular distribution

  • Use immunofluorescence to detect co-localization patterns

  • Assess whether CDK5R2-mediated phosphorylation affects CLOCK nuclear translocation

• Functional circadian readouts:

  • Monitor PER2::LUC bioluminescence in neuronal cultures with CDK5R2 manipulation

  • Assess period length, amplitude, and phase shifts

  • Compare with effects of CDK5R1 manipulation

• In vivo approaches:

  • Use conditional CDK5R2 knockout models to assess circadian behavioral rhythms

  • Measure core clock gene expression in the suprachiasmatic nucleus

  • Test phase-shifting responses to light pulses at different circadian times